HCV-ITEM: Human anti-Coronavirus vaccine that induces Specific Tecidual Immunity Multi-Epitope (Q2867174)

From EU Knowledge Graph
Revision as of 11:44, 20 January 2022 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in es, and other parts: Adding Spanish translations)
Jump to navigation Jump to search
Project Q2867174 in Portugal
Language Label Description Also known as
English
HCV-ITEM: Human anti-Coronavirus vaccine that induces Specific Tecidual Immunity Multi-Epitope
Project Q2867174 in Portugal

    Statements

    0 references
    470,365.0 Euro
    0 references
    500,000.0 Euro
    0 references
    94.07 percent
    0 references
    1 May 2020
    0 references
    28 February 2021
    0 references
    IMMUNETHEP, S.A.
    0 references
    0 references

    40°21'55.76"N, 8°39'29.95"W
    0 references
    Face à pandemia de COVID-19 e consequente urgência de soluções terapêuticas, o projeto VHC-ITEM visa a criação e prova de conceito de uma vacina inovadora, de aplicação intranasal, capaz de conferir elevada imunogenicidade face a potenciais mutações do vírus, pela utilização de SARS-CoV-2 atenuado. (Portuguese)
    0 references
    In view of the COVID-19 pandemic and consequent urgency of therapeutic solutions, the HCV-ITEM project aims to create and test the concept of an innovative vaccine, of intranasal application, capable of conferring high immunogenicity in the face of potential mutations of the virus, through the use of attenuated SARS-CoV-2. (English)
    7 July 2021
    0 references
    Compte tenu de la pandémie de COVID-19 et de l’urgence des solutions thérapeutiques qui en découle, le projet HCV-ITEM vise à créer et à prouver le concept d’un vaccin innovant, d’application intranasale, capable de conférer une immunogénicité élevée contre les mutations potentielles du virus, par l’utilisation du SARS-CoV-2 atténué. (French)
    4 December 2021
    0 references
    Angesichts der COVID-19-Pandemie und der daraus resultierenden Dringlichkeit therapeutischer Lösungen zielt das HCV-ITEM-Projekt darauf ab, das Konzept eines innovativen Impfstoffs mit intranasaler Anwendung zu schaffen und zu beweisen, das durch die Verwendung abgeschwächter SARS-CoV-2 eine hohe Immunogenität gegen potenzielle Mutationen des Virus verleihen kann. (German)
    13 December 2021
    0 references
    Gezien de COVID-19-pandemie en de daaruit voortvloeiende urgentie van therapeutische oplossingen heeft het HCV-ITEM-project tot doel het concept van een innovatief vaccin te creëren en te bewijzen, met intranasale toepassing, dat hoge immunogeniciteit kan verlenen tegen mogelijke mutaties van het virus door het gebruik van verzwakte SARS-CoV-2. (Dutch)
    18 December 2021
    0 references
    In considerazione della pandemia di COVID-19 e della conseguente urgenza di soluzioni terapeutiche, il progetto HCV-ITEM mira a creare e dimostrare il concetto di vaccino innovativo, con applicazione intranasale, in grado di conferire un'elevata immunogenicità contro potenziali mutazioni del virus, mediante l'uso di SARS-CoV-2 attenuato. (Italian)
    17 January 2022
    0 references
    En vista de la pandemia de COVID-19 y de la consiguiente urgencia de soluciones terapéuticas, el proyecto HCV-ITEM pretende crear y probar el concepto de vacuna innovadora, con aplicación intranasal, capaz de conferir una alta inmunogenicidad contra posibles mutaciones del virus, mediante el uso de SARS-CoV-2 atenuado. (Spanish)
    20 January 2022
    0 references
    Cantanhede
    0 references

    Identifiers

    CENTRO-01-02B7-FEDER-060491
    0 references